ZIM Laboratories Limited has announced that ACUITE Ratings & Research Limited has reaffirmed the credit ratings on the company's bank facilities. The pharmaceutical company disclosed this development to the stock exchanges on February 17, 2026, in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Credit Rating Details

ACUITE Ratings & Research Limited has reaffirmed ratings across two categories of bank facilities for ZIM Laboratories. The rating agency maintained its assessment of the company's creditworthiness across both long-term and short-term financial instruments.

Regulatory Compliance

The company communicated this rating reaffirmation to both BSE Limited and National Stock Exchange of India Limited through a formal intimation letter. ZIM Laboratories trades on BSE with scrip code 541400 and on NSE with the symbol ZIMLAB. The disclosure was signed by Piyush Nikhade, Company Secretary and Compliance Officer, ensuring adherence to regulatory requirements.

Company Operations

ZIM Laboratories operates with its manufacturing facility located at B-21/22, MIDC Area, Kalmeshwar in Nagpur district, Maharashtra. The company's registered office is situated at Sadoday Gyan, Nelson Square, Nagpur. As a pharmaceutical company, ZIM Laboratories focuses on innovation in medicine, as reflected in its tagline "ZeaL & Innovation in Medicine."

Zim laboratories has disclosed receiving a significant GST demand notice from Maharashtra tax authorities, marking a regulatory development that requires investor attention. The pharmaceutical company made this disclosure under SEBI regulations, providing detailed information about the tax demand and its planned response.

GST Demand Details

The company received a demand notice dated 30th December, 2025 from the Office of the Deputy Commissioner of State Tax, Nagpur, Maharashtra. The notice was issued under Section 73 of the Maharashtra Goods and Services Tax Act, 2017 for the financial year 2021-22.

Nature of Alleged Violation

The tax authorities have alleged that ZIM Laboratories availed excess input tax credit during FY 2021-22. The demand notice encompasses the principal GST amount along with applicable interest and penalty provisions under the Maharashtra GST Act.

Company's Response Strategy

ZIM Laboratories has outlined its approach to address the tax demand:

• Taking appropriate steps to assess the demand thoroughly
• Planning to file an appeal with concerned authorities
• Engaging with tax officials to understand the matter comprehensively
• Initiating appropriate follow-up actions

Disclosure Timeline and Compliance

The company acknowledged an inadvertent delay in making this disclosure, attributing it to the time required to approach concerned officials and understand the matter before initiating follow-up actions. The disclosure was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Impact Assessment

ZIM Laboratories has stated that it does not anticipate any material impact on the company's financials, operations, or other activities despite the substantial demand amount. The company's confidence appears to stem from its belief in the merit of its position and the availability of appellate remedies under the tax framework.